Luyan Pharma Co.,Ltd. (002788.SZ)
CNY 8.03
(-0.5%)
CNY 8.03
(-0.5%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 4.84 Billion CNY | -4.37% |
| 2022 | 5.06 Billion CNY | 13.19% |
| 2021 | 4.47 Billion CNY | 28.44% |
| 2020 | 3.48 Billion CNY | 7.01% |
| 2019 | 3.25 Billion CNY | 43.26% |
| 2018 | 2.27 Billion CNY | 26.68% |
| 2017 | 1.79 Billion CNY | 95.51% |
| 2016 | 917.01 Million CNY | -20.69% |
| 2015 | 1.15 Billion CNY | 2.5% |
| 2014 | 1.12 Billion CNY | 22.14% |
| 2013 | 923.49 Million CNY | 69.06% |
| 2012 | 546.25 Million CNY | 100.68% |
| 2011 | 272.2 Million CNY | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q2 | 6.14 Billion CNY | 21.99% |
| 2024 Q3 | 4.84 Billion CNY | -19.4% |
| 2024 Q1 | 5.03 Billion CNY | 4.07% |
| 2023 Q3 | 5.28 Billion CNY | 0.01% |
| 2023 Q4 | 4.84 Billion CNY | -8.35% |
| 2023 FY | 4.84 Billion CNY | -4.37% |
| 2023 Q1 | 5.18 Billion CNY | 2.37% |
| 2023 Q2 | 5.28 Billion CNY | 1.92% |
| 2022 Q4 | 5.06 Billion CNY | 4.43% |
| 2022 Q3 | 4.84 Billion CNY | 1.96% |
| 2022 Q2 | 4.75 Billion CNY | -4.5% |
| 2022 Q1 | 4.97 Billion CNY | 11.3% |
| 2022 FY | 5.06 Billion CNY | 13.19% |
| 2021 Q1 | 4.13 Billion CNY | 18.72% |
| 2021 Q2 | 4.18 Billion CNY | 1.36% |
| 2021 Q3 | 4.4 Billion CNY | 5.16% |
| 2021 Q4 | 4.47 Billion CNY | 1.49% |
| 2021 FY | 4.47 Billion CNY | 28.44% |
| 2020 Q4 | 3.48 Billion CNY | -3.42% |
| 2020 Q1 | 3.82 Billion CNY | 17.56% |
| 2020 Q2 | 3.67 Billion CNY | -3.93% |
| 2020 FY | 3.48 Billion CNY | 7.01% |
| 2020 Q3 | 3.6 Billion CNY | -1.9% |
| 2019 Q4 | 3.25 Billion CNY | 0.77% |
| 2019 FY | 3.25 Billion CNY | 43.26% |
| 2019 Q3 | 3.22 Billion CNY | 3.67% |
| 2019 Q2 | 3.11 Billion CNY | 7.08% |
| 2019 Q1 | 2.9 Billion CNY | 28.06% |
| 2018 FY | 2.27 Billion CNY | 26.68% |
| 2018 Q1 | 2.18 Billion CNY | 21.87% |
| 2018 Q2 | 2.3 Billion CNY | 5.72% |
| 2018 Q3 | 2.33 Billion CNY | 1.05% |
| 2018 Q4 | 2.27 Billion CNY | -2.71% |
| 2017 Q1 | 1.09 Billion CNY | 19.78% |
| 2017 Q2 | 1.79 Billion CNY | 63.61% |
| 2017 FY | 1.79 Billion CNY | 95.51% |
| 2017 Q4 | 1.79 Billion CNY | -15.11% |
| 2017 Q3 | 2.11 Billion CNY | 17.53% |
| 2016 Q4 | 917.01 Million CNY | -29.15% |
| 2016 Q3 | 1.29 Billion CNY | -13.14% |
| 2016 Q2 | 1.49 Billion CNY | 11.16% |
| 2016 Q1 | 1.34 Billion CNY | 15.93% |
| 2016 FY | 917.01 Million CNY | -20.69% |
| 2015 Q3 | 1.36 Billion CNY | 0.0% |
| 2015 Q4 | 1.15 Billion CNY | -15.6% |
| 2015 FY | 1.15 Billion CNY | 2.5% |
| 2015 Q1 | - CNY | 0.0% |
| 2014 FY | 1.12 Billion CNY | 22.14% |
| 2013 FY | 923.49 Million CNY | 69.06% |
| 2012 FY | 546.25 Million CNY | 100.68% |
| 2011 FY | 272.2 Million CNY | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Cachet Pharmaceutical Co., Ltd. | 4.01 Billion CNY | -20.445% |
| Yixintang Pharmaceutical Group Co., Ltd. | 4.88 Billion CNY | 0.937% |
| ZJAMP Group Co., Ltd. | 2.88 Billion CNY | -67.642% |
| Ji Yao Holding Group Co., Ltd. | 1.44 Billion CNY | -234.167% |